| Pair Name | Pristimerin, Gemcitabine | ||
| Phytochemical Name | Pristimerin (PubChem CID: 159516 ) | ||
| Anticancer drug Name | Gemcitabine (PubChem CID: 60750 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Pristimerin, Gemcitabine | |||
| Disease Info | [ICD-11: 2C10.0] | Pancreatic ductal adenocarcinoma | Investigative | |
| Biological Phenomena | Induction-->DNA damage | |||
| Gene Regulation | Down-regulation | Phosphorylation | CHEK1 | hsa1111 |
| Down-regulation | Expression | TP53 | hsa7157 | |
| In Vitro Model | AsPC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0152 |
| BxPC-3 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0186 | |
| PANC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0480 | |
| Result | These results show that pristimerin acts as a naturally occurring inhibitor of RSR, and a novel therapeutic strategy of combining pristimerin and gemcitabine deserves further detailed investigation in PC models in vivo. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Pristimerin synergizes with gemcitabine through abrogating Chk1/53BP1-mediated DNA repair in pancreatic cancer cells. Food Chem Toxicol. 2021 Jan;147:111919. doi: 10.1016/j.fct.2020.111919. | Click |
